The at-home vaccine is the same as regular FluMist, which is approved for ages two through 49. That means babies and older ...

The U.S. Food and Drug Administration (FDA) has approved FluMist — the nasal spray flu vaccine — for home use by a patient or adult caregiver, the agency announced. FluMist has been in use for a ...

The FDA has approved a new flu vaccine nasal spray for at-home use. While this self-administered version won't be available for this year's flu season, interest in nasal spray products is growing. A ...

The FDA has approved an at-home nasal spray flu vaccine, and it’s now available for order. FluMist enters the bloodstream after being sprayed in your nasal passage and helps build up antibodies to ...

Gaithersburg, Maryland-based MedImmune has received the Food and Drug Administration’s approval for self- or caregiver-administration of its FluMist nasal spray flu vaccine, meaning no physician ...

HUNTINGTON, W.Va. (WSAZ) - The FDA has approved a new emergency treatment for allergic reactions in the form of a nasal spray. FDA officials say this is the first epinephrine product for anaphylaxis ...

FILE - Food and Drug Administration (FDA) building is shown in Silver Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File) (Manuel Balce Ceneta, Copyright ...

A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) ...

WASHINGTON -- Regulators at the U.S. Food and Drug Administration declined to approve a needle-free nasal spray equivalent to an EpiPen, pending further study, according to the company developing it.

For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monotherapy for adults with major depressive ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...